Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S. · 2021

Read Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. by Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8078907.txt.

Introduction

Monin and co-authors test how well one or two vaccine doses protect patients with cancer. The Pfizer-BioNTech vaccine's record in such patients was unknown. The team recruited from three London hospitals starting in December 2020. The cohort held 151 patients with cancer and 54 healthy controls. Blood was drawn before dosing and at set weeks after.

Three weeks after one dose, 94% of healthy controls had anti-spike antibodies. Only 38% of patients with solid cancers reached that mark. Patients with blood cancers fared worst, at 18% after the single dose. A second dose at day 21 lifted responses in those who got it. Safety signals stayed in line with the general population. The interim results argue against long dose delays for cancer patients. Their weak first response needs the prompt boost.

Catalog record

CREATORMonin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8078907

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study By Leticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar Published in: The Lancet. Oncology DOI: 10.1016/S1470-2045(21)00213-8 ABSTRACT Summary Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer. Methods For this prospective observational study, we recruited patients with cancer and healthy controls (mostly health-care workers) from three London hospitals between Dec 8, 2020, and Feb 18, 2021. Participants who were vaccinated between Dec 8 and Dec 29, 2020, received two 30 μg doses of BNT162b2 administered intramuscularly 21 days apart; patients vaccinated after this date received only one 30 μg dose with a planned follow-up boost at 12 weeks. Blood samples were taken before vaccination and at 3 weeks and 5 weeks after the first vaccination. Where possible, serial nasopharyngeal real-time RT-PCR (rRT-PCR) swab tests were done every 10 days or in cases of symptomatic COVID-19. The coprimary endpoints were seroconversion to SARS-CoV-2 spike (S) protein in patients with cancer following the first vaccination with the BNT162b2 vaccine and the effect of vaccine boosting after 21 days on seroconversion. All participants with available data were included in the safety and immunogenicity analyses. Ongoing follow-up is underway for further blood sampling after the delayed (12-week) vaccine boost. This study is registered with the NHS Health Research Authority and Health and Care Research Wales (REC ID 20/HRA/2031). Findings 151 patients with cancer (95 patients with solid cancer and 56 patients with haematological cancer) and 54 healthy controls were enrolled. For this interim data analysis of the safety and immunogenicity of vaccinated patients with cancer, samples and data obtained up to March 19, 2021, were analysed. After exclusion of 17 patients who had been exposed to SARS-CoV-2 (detected by either antibody seroconversion or a positive rRT-PCR COVID-19 swab test) from the immunogenicity analysis, the proportion of positive anti-S IgG titres at approximately 21 days following a single vaccine inoculum across the three cohorts were 32 (94%; 95% CI 81–98) of 34 healthy controls; 21 (38%; 26–51) of 56 patients with solid cancer, and eight (18%; 10–32) of 44 patients with haematological cancer. 16 healthy controls, 25 patients with solid cancer, and six patients with haematological cancer received a second dose on day 21. Of the patients with available blood samples 2 weeks following a 21-day vaccine boost, and excluding 17 participants with evidence of previous natural SARS-CoV-2 exposure, 18 (95%; 95% CI 75–99) of 19 patients with solid cancer, 12 (100%; 76–100) of 12 healthy controls, and three (60%; 23–88) of five patients with haematological cancers were seropositive, compared with ten (30%; 17–47) of 33, 18 (86%; 65–95) of 21, and four (11%; 4–25) of 36, respectively, who did not receive a boost. The vaccine was well tolerated; no toxicities were reported in 75 (54%) of 140 patients with cancer following the first dose of BNT162b2, and in 22 (71%) of 31 patients with cancer following the second dose. Similarly, no toxicities were reported in 15 (38%) of 40 healthy controls after the first dose and in five (31%) of 16 after the second dose. Injection-site pain within 7 days following the first dose was the most commonly reported local reaction (23 [35%] of 65 patients with cancer; 12 [48%] of 25 healthy controls). No vaccine-related deaths were reported. Interpretation In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine. Funding King's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute. Research in contextEvidence before this studyFollowing SARS-CoV-2 infection, some patients with cancer, especially those with haematological malignancies, had sustained immune dysregulation, inefficient seroconversion, and prolonged viral shedding. To identify studies reporting on immunological responses to COVID-19 vaccines in patients with cancer, we searched PubMed for articles published in English between Jan 1 and Dec 1, 2020, using the search terms (“cancer” or “malignancy”) AND (“Vaccine” OR “mRNA vaccine”) AND (“COVID-19” OR “coronavirus” OR “SARS-CoV-2”). However, exclusion of patients with cancer and, in particular, those receiving systemic anticancer therapies from the registry trials of the five approved COVID-19 vaccines raised questions about the efficacy and safety of vaccination against SARS-CoV-2 in this patient population. Additionally, although the change in the UK's dosing interval to 12 weeks between vaccine doses was implemented to maximise vaccine coverage in the general population, it is unclear whether this strategy is appropriate for patients with cancer and those on systemic anticancer therapies.Added value of this studyIn this prospective observational study of 151 patients with solid and haematological cancers, we provide the first insights, to our knowledge, into the antibody and T-cell responses to the mRNA-based SARS-CoV-2 BNT162b2 vaccine, as well as its safety, in an immunocompromised patient population. We also assess the consequence of using different dosing schedules in this population. In patients with cancer, one 30 μg dose of the BNT162b2 vaccine yields poor efficacy, as measured by seroconversion rates, viral neutralisation capacity, and T-cell responses, at 3 weeks and 5 weeks following the first inoculum. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose.Implications of all the available evidenceOur data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing and careful follow-up should be prioritised for these patients, together with vaccination of those in close contact with them, in order to promote herd immunity. INTRODUCTION As part of the UK's programme to control the spread of SARS-CoV-2, the Medicines and Healthcare products Regulatory Agency (MHRA) authorised the SARS-CoV-2 mRNA vaccine BNT162b2 (produced by Pfizer–BioNTech; Mainz, Germany) on Dec 2, 2020, for active immunisation to prevent COVID-19 in individuals aged 16 years and older.1 Since immunocompetence can be jeopardised by malignancy or its treatment, or both,2, 3, 4 patients with cancer were among the groups prioritised for vaccination. The phase 3 trial of the BNT162b2 vaccine showed 95% efficacy in preventing COVID-19, including severe disease.5 However, of the 18 860 vaccinated individuals in the trial, none with an active oncological diagnosis was included. Exclusion criteria included a medical history of COVID-19, treatment with immunosuppressive therapy, or diagnosis of an immunocompromising condition. On Dec 30, 2020, the UK Government announced that for all priority groups, second doses of the COVID-19 vaccines should be given after approximately 12 weeks rather than 3–4 weeks as was initially recommended by the manufacturing license. On Feb 12, 2021, the UK Government's Green Book, chapter 14a, was updated with a note of caution about possible low vaccine responses in immunosuppressed

Read the complete text